Can we use neutrophil to lymphocyte ratio in the diagnosis and prediction of extracapsular extension in localized prostate cancer?

2021 ◽  
pp. 039156032110148
Author(s):  
Erkan Merder ◽  
Ahmet Arıman ◽  
Selvi Dinçer ◽  
Fatih Altunrende
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Neutrophil To Lymphocyte Ratio ◽  
Localized Prostate Cancer ◽  
Extracapsular Extension ◽  
Lymphocyte Ratio ◽  
Pathologic Stage ◽  
Free Psa

Purpose: We investigated role of neutrophil-to-lymphocyte ratio (NLR) in the diagnosis and prediction of extracapsular extension (ECE) in clinically localized prostate cancer (PCa). Materials and methods: A total of 396 patients with clinically localized PCa who underwent open radical retropubic prostatectomy (RRP), and 260 patients with benign prostatic hyperplasia (BPH) who underwent suprapubic prostatectomy were included in the study. Preoperative NLR, prostate specific antigen (PSA), prostate specific antigen density (PSAD), free PSA, prostate volume (PV), free/total PSA (f/t PSA) in both groups, and relation of NLR with PSA, Gleason Score (GS), and pathologic stage in PCa group were investigated. Records of patients were analyzed retrospectively. Results: NLR, free PSA, f/t PSA, and PV were statistically higher in BHP, and PSAD was higher in PCa group. In PCa group, NLR was found to be higher in patients with PSA >10 ng/ml compared to those with less than ⩽10 ng/ml. NLR increases as the preoperative GS increases, and it was higher in pT3 patients than pT2 patients. NLR was statistically higher in those patients with positive lymph nodes than those without after RRP ( p = 0.029). Conclusion: NLR is not a sufficient biomarker in differentiating clinically localized PCa from BPH. NLR increases as preoperative GS and pathologic stage increases. Lymph node involved patients after RRP have statistically higher NLR. NLR can be an indicator of ECE and lymph-node involvement in clinically localized PCa.

Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer

Urology ◽  
1997 ◽  
Vol 49 (5) ◽  
pp. 716-720 ◽  
Author(s):  
Ralf Thiel ◽  
Jay D. Pearson ◽  
Jonathan I. Epstein ◽  
Patrick C. Walsh ◽  
H. Ballentine Carter
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Localized Prostate Cancer ◽  
Pathologic Stage

The role of blood neutrophil count and the neutrophil-to-lymphocyte ratio as a predictive factor for prostate biopsy results

2018 ◽  
Vol 85 (4) ◽  
pp. 158-162 ◽  
Author(s):  
Koosha Kamali ◽  
Mojtaba Ashrafi ◽  
Pejman Shadpour ◽  
Mojtaba Ameli ◽  
Amirmahdi Khayyamfar ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Neutrophil Count ◽  
Prostate Biopsy ◽  
Predictive Factor ◽  
Specific Antigen ◽  
Digital Rectal Examination ◽  
Neutrophil To Lymphocyte Ratio ◽  
Blood Neutrophil ◽  
Lymphocyte Ratio

Background: It is apparent that prostate cancer has harmful effects on the erythrocytes, leucocytes, and platelets. In addition, it has been suggested that the toxic granules in neutrophils lead to inflammation in the cancerous tissues besides the activation of monocytes, so in this study we aimed to evaluate the blood neutrophil count besides the neutrophil-to-lymphocyte ratio as a predictive factor for prostate biopsy results and their relationship with prostate cancer grade in patients undergoing biopsy of the prostate. Methods: For all men with irritative lower urinary tract symptoms visiting Hasheminezhad Hospital from January to July 2015, in case of having a suspicious digital rectal examination or aged above 40 years, prostate-specific antigen was requested and in case of abnormal results, they underwent prostate biopsy. In order to examine the study hypothesis, the blood neutrophil count and the neutrophil-to-lymphocyte ratio were measured and compared with the abnormal prostate-specific antigen results and suspicious digital rectal examination. Results: Among the 500 referred samples for biopsy, 352 (70.4%) had a negative biopsy result, while it was positive in the other 148 (29.6). The mean neutrophil count showed no statistical difference regarding the biopsy results (p = 0.381). When measuring the neutrophil-to-lymphocyte ratio again with biopsy results, no statistically significant difference was obtained based on the biopsy results (p = 0.112). Conclusion: Neutrophil count and neutrophil-to-lymphocyte ratio cannot be predictive factors for positive prostate cancer biopsy.

Value of Percent Free Prostate-Specific Antigen for the Prediction of Pathological Stage in Men with Clinically Localized Prostate Cancer

2002 ◽  
Vol 17 (4) ◽  
pp. 239-243 ◽  
Author(s):  
J. Morote ◽  
E. Trilla ◽  
S. Esquena ◽  
F. Serrallach ◽  
J.M. Abascal ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Gleason Score ◽  
Clinical Stage ◽  
Specific Antigen ◽  
Localized Prostate Cancer ◽  
Pathological Features ◽  
Pathological Stage ◽  
Additional Information ◽  
Free Psa

Purpose To analyze if the percentage of free prostate-specific antigen (PSA) can provide additional information to the combination of local clinical stage, serum PSA and Gleason score in the prediction of final stage and pathological features of prostate cancer. Materials and Methods A group of 480 men with clinically localized prostate cancer underwent lymphadenectomy and radical prostatectomy. Total and free PSA were measured in preoperative serum. Clinical stage was T1 in 70.4% of patients and T2 in 29.6%. The biopsy Gleason score ranged between 2 and 4 in 5.6%, between 5 and 7 in 78.4%, and was higher than 7 in 16%. Total serum PSA was below 4.1 ng/mL in 4.3%, between 4.1 and 10 ng/mL in 66.4%, between 10.1 and 20 ng/mL in 22.5%, and higher than 20 in 6.7% of patients. The tumor was organ-confined in 49.8% and specimen-confined in 64.2%, and its pathological features were favorable in 35%. Results Multiple logistic regression analysis demonstrated that percent free PSA has independent predictive value for pathological stage only in the subset of patients with cT1 tumors and serum PSA between 4.1 and 10 ng/mL. In this group the probability of organ-confined cancer was 68.3% if the percent free PSA was above 15 and 56.3% if it was lower (p<0.001). The probability of specimen-confined disease was 86.6% and 71.3%, respectively (p<0.007), and the probability of favorable pathology was 59.8% and 39.6%, respectively (p<0.002). We also found higher rates of organ- and specimen-confined tumors and favorable pathology for every Gleason score when the percent free PSA was higher than 15. Conclusions Percent free PSA seems to provide additional information to the combination of clinical stage and Gleason score for the prediction of pathological features only in patients with clinical stage T1c and serum PSA between 4.1 and 10 ng/mL.

Value of Percent Free Prostate-Specific Antigen for the Prediction of Pathological Stage in Men with Clinically Localized Prostate Cancer

2002 ◽  
Vol 17 (4) ◽  
pp. 239-243 ◽  
Author(s):  
J. Morote ◽  
E. Trilla ◽  
S. Esquena ◽  
F. Serrallach ◽  
J.M. Abascal ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Gleason Score ◽  
Clinical Stage ◽  
Specific Antigen ◽  
Localized Prostate Cancer ◽  
Pathological Features ◽  
Pathological Stage ◽  
Additional Information ◽  
Free Psa

Purpose To analyze if the percentage of free prostate-specific antigen (PSA) can provide additional information to the combination of local clinical stage, serum PSA and Gleason score in the prediction of final stage and pathological features of prostate cancer. Materials and Methods A group of 480 men with clinically localized prostate cancer underwent lymphadenectomy and radical prostatectomy. Total and free PSA were measured in preoperative serum. Clinical stage was T1 in 70.4% of patients and T2 in 29.6%. The biopsy Gleason score ranged between 2 and 4 in 5.6%, between 5 and 7 in 78.4%, and was higher than 7 in 16%. Total serum PSA was below 4.1 ng/mL in 4.3%, between 4.1 and 10 ng/mL in 66.4%, between 10.1 and 20 ng/mL in 22.5%, and higher than 20 in 6.7% of patients. The tumor was organ-confined in 49.8% and specimen-confined in 64.2%, and its pathological features were favorable in 35%. Results Multiple logistic regression analysis demonstrated that percent free PSA has independent predictive value for pathological stage only in the subset of patients with cT1 tumors and serum PSA between 4.1 and 10 ng/mL. In this group the probability of organ-confined cancer was 68.3% if the percent free PSA was above 15 and 56.3% if it was lower (p<0.001). The probability of specimen-confined disease was 86.6% and 71.3%, respectively (p<0.007), and the probability of favorable pathology was 59.8% and 39.6%, respectively (p<0.002). We also found higher rates of organ- and specimen-confined tumors and favorable pathology for every Gleason score when the percent free PSA was higher than 15. Conclusions Percent free PSA seems to provide additional information to the combination of clinical stage and Gleason score for the prediction of pathological features only in patients with clinical stage T1c and serum PSA between 4.1 and 10 ng/mL.

The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer

Urology ◽  
1996 ◽  
Vol 48 (6) ◽  
pp. 51-54 ◽  
Author(s):  
Jürgen Pannek ◽  
Eric N.P. Subong ◽  
Kerrie A. Jones ◽  
Penny L.S. Marschke ◽  
Jonathan I. Epstein ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Localized Prostate Cancer ◽  
Pathologic Stage ◽  
Total Prostate Specific Antigen
Sign in / Sign up

Export Citation Format

Share Document